Longevity science and the biology of aging
October 23, 2026 — The experimental gene therapy borrows tools that can reset a cell’s identity. Its more delicate goal is to recover function without making the cell start over.
October 15, 2026 — An October 2026 randomized trial reported fibrosis improvement with dasatinib plus quercetin in MASH. The biopsy signal is promising but comes from a small trial.
October 15, 2026 — An October 2026 Immunity study compares immune-cell patterns in 2,609 people. Learn why the granzyme K/B ratio is promising but not a clinical aging test.
October 14, 2026 — Why Bonn’s slow blood-to-neural-stem-cell conversion may help aging research, and why a younger molecular clock is not proof of human rejuvenation.
October 14, 2026 — A 12-week NR trial raised blood NAD+ but found no statistically significant cognitive benefit in older adults with amnestic mild cognitive impairment.
October 14, 2026 — Life Biosciences reports early tolerability in three ER-100 participants and visual-field changes in two. Controlled efficacy remains unproven.
October 10, 2026 — A promising cell experiment and a useful health decision operate on different clocks. We can take the research seriously without waiting for it to become a treatment.